65 related articles for article (PubMed ID: 23174593)
21. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters.
Hashmi AA; Edhi MM; Naqvi H; Khurshid A; Faridi N
Breast J; 2014; 20(6):578-85. PubMed ID: 25219294
[TBL] [Abstract][Full Text] [Related]
24. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
25. Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer.
Bi X; Wu C; Han M; Cai J
Gland Surg; 2012 May; 1(1):12-9. PubMed ID: 25083422
[TBL] [Abstract][Full Text] [Related]
26. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
29. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
30. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
31. Gene-expression analysis and the basal-like breast cancer subtype.
Finnegan TJ; Carey LA
Future Oncol; 2007 Feb; 3(1):55-63. PubMed ID: 17280502
[TBL] [Abstract][Full Text] [Related]
32. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients.
Ben Abdelkrim S; Trabelsi A; Missaoui N; Beizig N; Bdioui A; Anjorin A; Jomaa W; Mokni M
Pathol Res Pract; 2010 Nov; 206(11):772-5. PubMed ID: 20850937
[TBL] [Abstract][Full Text] [Related]
33. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
Nakai E; Park K; Yawata T; Chihara T; Kumazawa A; Nakabayashi H; Shimizu K
Cancer Invest; 2009 Nov; 27(9):901-8. PubMed ID: 19832037
[TBL] [Abstract][Full Text] [Related]
34. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
[TBL] [Abstract][Full Text] [Related]
37. Identification of different subtypes of breast cancer using tissue microarray.
Munirah MA; Siti-Aishah MA; Reena MZ; Sharifah NA; Rohaizak M; Norlia A; Rafie MK; Asmiati A; Hisham A; Fuad I; Shahrun NS; Das S
Rom J Morphol Embryol; 2011; 52(2):669-77. PubMed ID: 21655659
[TBL] [Abstract][Full Text] [Related]
38. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
Taheri M; Mahjoubi F; Omranipour R
Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
[TBL] [Abstract][Full Text] [Related]
39. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
40. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
